You searched for "vision"

2495 results found

Progression of myopic maculopathy after treatment

The authors report on a retrospective study carried out to evaluate long-term progression of myopic maculopathy and functional outcome in eyes treated for myopic choroidal neovascularisation (CNV) and in eyes without CNV. Fifty-four myopic eyes of 30 patients were included...

Inner nuclear layer of the retina showing increase in thickness in diabetic macular oedema

Diabetic retinopathy is one of the leading causes of blindness in the developed world. With optical coherence tomography (OCT), it has become possible to image the retina in vivo and to measure retinal oedema by measuring retinal thickness (RT) with...

Moxifloxacin 0.5% for bacterial keratitis

The authors report on the results of a randomised controlled trial comparing commercially available non-preserved moxifloxacin 0.5% vs. a combination of fortified cefazolin 5% and tobramycin 1.3% in the treatment of moderate bacterial keratitis without perforation. Corneal scrapings were collected...

Visual acuity outcomes in Coat’s disease by classification stage

This is a retrospective study of 160 consecutive patients with Coat’s disease under the Shields classification, with Snellen visual acuity (VA) pre and post treatment. Affected eyes were categorised based on the Shields classification: Stage 1: retinal telangiectasia onlyStage 2a:...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

How does low-concentration atropine reduce progression of myopia?

This is a double-blind, randomised, placebo-controlled trial evaluating the effects of low-concentration atropine (0.05%, 0.025%, 0.01%) on ocular biometrics of myopic children. The aim is to determine what aspect of ocular biometrics low-concentration atropine influenced in reducing the progression of...

Efficacy and safety of novel PF brimonidine / timolol fixed-combination ophthalmic solution for OAG

This study is a multicentre, randomised, open-label, parallel-group clinical trial to evaluate the efficacy and safety of a newly developed preservative-free (PF) brimonidine / timolol fixed-combination (BTFC) ophthalmic solutions as compared with preservative-containing (PC) BTFC ophthalmic solution in adult patients...

Does pregnancy cause progression of keratoconus in previously cross-linked corneas?

This is a prospective study involving 24 eyes of 19 patients with stabilised or regressed keratoconus after a successful accelerated cross linking (A-CXL) treatment. Patients were recruited at a routine follow-up visit in the first month of their pregnancy. The...

Are illness perception or personality factors associated with follow-up appointment attendance in neuro-ophthalmology?

This was a prospective study which surveyed adults with appointments in either neuro-ophthalmology or the glaucoma service at a tertiary clinic. The aim of the study was to identify factors linked to attendance of follow-up appointments. Recruitment occurred over a...

Long-term outcomes of using intraoperative relaxed muscle positioning technique in thyroid eye disease

The authors present a retrospective case review of consecutive patients undergoing ocular muscle surgery by one ophthalmologist using the intraoperative relaxed muscle positioning (IRMP) technique for thyroid eye disease (TED)-associated strabismus over a 23-year period. The following data were extracted...

Jessica Bartlett joins Glaukos as Territory Manager, North West England / Yorkshire

Glaukos Corporation is delighted to announce the appointment of Jessica Bartlett to the position of Territory Manager, Northwest, and Yorkshire.

Stent inject® W shelf life extended from 12 months to three years

Glaukos is delighted to announce that the expiry date for their innovative iStent inject® W device has been increased from 12 months to three years.